Palliative Care and Prognosis of Men with Metastasized Breast Cancer R. Foerster¹; F. Foerster^{2,3}; V. Wulff⁴; B. Schubotz⁵; R. Lange⁵; J.-O. Habeck⁶; D. Baaske⁷; C. Rudlowski⁸

(1) Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic; (2) Outpatient Department of Gynecological Oncology and Palliative Care, Poliklinik GmbH, Chemnitz, Germany; (3) Department of Economical Sciences, University of Applied Sciences, Zwickau, Germany; (4) Cancer Register of Chemnitz, Chemnitz, Germany; (6) Department of Pathology, Klinikum Chemnitz, Chemnitz, Germany; (7) Department of Radiooncology, Klinikum Chemnitz, Germany; (8) Department of Gynecology and Obstetrics, University Hospital, Bonn, Germany

BACKGROUND

About 1% of breast cancer occur in men (MBC) No publications on palliative care and prognosis of men with metastasized breast cancer available

OBJECTIVE


•Analysis of the significance of systemic oncologic treatments within the framework of complex palliative care (CPC) (n=24; 64.9%) vs. best supportive care alone (BSC) (n=13; 35.1%)

PATIENTS & METHODS


2. Therapeutic Management

Complex palliative care (CPC) consisted of: chemotherapy, endocrine therapy, radiation therapy, pain control, bisphosphonates, transfusion, pleura puncture, pleurodesis, complementary treatments, physiotherapy,

ergotherapy, psychotherapy, wound management (Fig. 1)



Tumor size (Fig. 4), nodal state (Fig. 5) und grading (Fig. 6) did not have significant influence on overall survival



Scientific evaluation of all patients with MBC (n=127) listed in the cancer registers of the cities Chemnitz and Zwickau, District of Chemnitz, Saxony, Germany 1995-2009 Identification of 37 men with metastasized MBC including 13 cases (35.1%) with primary metastasis Statistical analysis with χ^2 test and Log-Rank test

RESULTS

1. Patients' Characteristics

Patients' characteristics according to treatment cohorts are shown in table 1 and according to time of diagnosis of metastasis in table 2

Tab. 1: Patients' characteristics and treatment cohort

		СРС		BSC			Total		
Ν		24	64.9%		13	35.1%		37	100%
Age		43-81		51-80		43-81			
Age (average)		62,42		71,31		65,64			
Histopathology	n=24			n=13			n=37		
Invasive-ductal ca.		23	95.8%		8	61.5%		31	83.8%
Others		1	4.2%		5	38.5 %		6	16.2%
<u>Tumor size</u>	n=24			n=13			n=37		
Τ1		7	29.2%		5	38.5 %		12	32.4%
T2		10	41.6%		2	15.4%		12	32.4%
ТЗ		1	4.2%		1	7.7%		2	5.5%
Т4		6	25%		5	38.4 %		11	29.7 %
Nodal state	n=23			n=10			n=33		
N+		13	56.5 %		4	40%		17	51.5%
N-		10	43.5 %		6	60%		16	48.5 %
<u>Grading</u>	n=24			n=9			n=33		
G1		1	4.2%		0	0%		1	3%
G2		15	62.5%		4	44.4%		19	57.6%
G3		8	33.3%		5	55.6%		13	39.4 %
Hormone receptor	n=22			n=9			n=31		
HR+		20	90.9%		6	66.7%		26	83.9%
HR-		2	9.1%		3	33.3%		5	16.1%
HER2 receptor	n=18			n=8			n=26		
HER2+		2	11.1%		1	12.5%		3	11.5%
HER2-		16	88.9%		7	87.5 %		23	88.5%



3. Sites of Metastasis

Most common sites for occurrence of metastasis were bone, liver and lung (Fig. 2)

15

10




Fig. 4: Initial tumor size und survival (n.s.)





Fig. 5: Lymph node involvement and survival (n.s.)



Tab. 2: Patients' characteristics and time of occurrence of metastasis

	F	Prima	ary	Seco	ndary	
	metastasized			metastasized		
N		13	35.1%	24	64.9%	
Age		43-7	' 9	44	-81	
Age (average)		66,1	.5	65	5,21	
Histopathology	n=13			n=24		
Invasive-ductal ca.		8	61.5%	23	95.8%	
Others		5	38.5%	1	4.2%	
Tumor size	n=13			n=24		
T1		1	7.7%	11	45.8%	
T2		4	30.7%	8	33.4%	
ТЗ		2	15.4%	0	0%	
T4		6	46.2%	5	20.8%	
Nodal state	n=10			n=23		
N+		8	80%	9	60.9%	
N -		2	20%	14	39.1%	
<u>Grading</u>	n=10			n=23		
G1		0	0%	1	4.3%	
G2		3	30%	16	69.6%	
G3		7	70%	6	26.1%	
Hormone receptor	n=11			n=20		
HR+		9	81.2%	17	85%	
HR-		2	18.8%	3	15%	
HER2 receptor	n=9			n=17		
HER2+		2	22.2%	1	5.9%	
HER2-		7	77.8%	16	94.1%	

Fig. 2: Sites of metastasis

4. Survival

1.0-

Improvement of survival with the help of complex palliative care vs. best supportive care alone (Fig. 3; p=.001)

-	CPC vs. BSC

Fig. 6: Grading und survival (n.s.)

Negative hormone receptor (HR) state did correlate with significantly (p<.001) worse overall survival (Fig. 7)




Fig. 7: HR state und survival (p<.001)

DISCUSSION & CONCLUSIONS

Integration of systemic therapies into the palliative treatment concept for improvement of quality of life and overall survival




Fig. 3: Overall survival CPC vs. BSC (p=.001)

Benefit also for patients with far advanced tumor disease with respect to performance index and phase of live and/or therapy

liklinik GmbH Chem.

REFERENCES

Klinikum Chemnitz gGmbH Academic Teaching Hospital of the Universities of Leipzig and Dr Member of the German Network of Health Promoting Hospitals

Giordano S et al., Cancer 2004 Jul 1; 101 (1): 51-7 Gennari R et al. Int J Oncol. 2004 Mar; 24(3): 663-70 Kantarjian H et al., Arch Intern Med, 1983 Feb; 143 (2): 237-40 Lopez M et al., Oncology, 1985; 42(6): 345-9 •Kraybill WG et al., Cancer, 1981 May 1; 47(9):2185-9 Patterson JS et al., Cancer Treat Rep, 1980 Jun-Jul; 64(6-7): 801-4

18th Int. Congress on Palliative Care, Montreal, QC, Canada, 2010

